Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis [PDF]
, 2016 Objectives: To assess structural damage progression with subcutaneous abatacept (ABA) in the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) trial following abrupt withdrawal of all rheumatoid arthritis (RA) medication in patients achieving ...
Baker +29 more
core +3 more sources
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
New England Journal of Medicine, 2020 BACKGROUND Upadacitinib is an oral selective Janus kinase inhibitor to treat rheumatoid arthritis. The efficacy and safety of upadacitinib as compared with abatacept, a T-cell costimulation modulator, in patients with rheumatoid arthritis refractory to ...
A. Rubbert-Roth +8 more
semanticscholar +1 more source
PLoS ONE, 2022 BackgroundsTreating asthmatic rheumatoid arthritis patients with abatacept has been shown to associate with better control of asthma symptoms. However, the mechanism behind that is not investigated.MethodsOvalbumin (OVA)- sensitized BALB/c female mice ...
Maha Fahad Alenazy +15 more
doaj +1 more source
Squamous-cell carcinoma of the tongue following therapy of rheumatoid arthritis with abatacept [PDF]
, 2014 A patient affected by rheumatoid arthritis developed a squamous-cell carcinoma probably due to abatacept, according to Naranjo algorithm. The case describes this adverse reaction for the first time and highlights the need for additional studies to ...
Deidda, Arianna +7 more
core +1 more source
Immunomodulatory mechanisms of abatacept: A therapeutic strategy for COVID-19
Frontiers in Medicine, 2022 Coronavirus disease 2019 (COVID-19) caused by coronavirus-2 (SARS-CoV-2) infection has rapidly spread throughout the world and become a major threat to human beings. Cytokine storm is a major cause of death in severe patients.
Dinglong Yang +6 more
doaj +1 more source
Effectiveness of abatacept for patients with Sjögren’s syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren’s syndrome Endocrinopathy) trial [PDF]
, 2016 Objective: To clarify the efficacy and safety of abatacept for secondary Sjögren’s syndrome (SS) associated with rheumatoid arthritis (RA).Methods: The primary endpoint of this open-labeled, prospective, observational multicenter study for secondary SS ...
Asashima Hiromitsu +28 more
core +1 more source
Advances in Rheumatology, 2023 Background Our aim was to compare the efficacy of rituximab, tocilizumab, and abatacept in individuals with rheumatoid arthritis (RA) refractory to treatments with MTX or TNFi agents.
A. Pugliesi +8 more
semanticscholar +1 more source
Effects of CTLA4-Ig on human monocytes
Inflammation and Regeneration, 2017 Background Abatacept, a CTLA4-Ig fusion protein attenuates T cell activation by inhibiting the CD80/86-CD28 costimulatory pathway that is required for the proper T cell activation and thus displays beneficial effects in the treatment of rheumatoid ...
Toshihiro Tono +5 more
doaj +1 more source
Cells, 2023 Abatacept (CTLA4-Ig)—a monoclonal antibody which restricts T cell activation—is an effective treatment for rheumatoid arthritis (RA). Nevertheless, only 50% of RA patients attain clinical responses, while predictors of response are rather limited. Herein,
P. Goutakoli +12 more
semanticscholar +1 more source
Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial. [PDF]
Arthritis RheumatolOur objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks.
Aggarwal R +5 more
europepmc +2 more sources